Compounds > aconiazide
Page last updated: 2024-12-11

aconiazide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5391612
MeSH IDM0091356

Synonyms (19)

Synonym
aconiazide
aconiazidum [inn-latin]
brn 0300804
isonicotinic acid, (o-(carboxymethoxy)benzylidene)hydrazide
phenoxalid
compound 377
4-pyridinecarboxylic acid, ((2-(carboxymethoxy)phenyl)methylene)hydrazide
aconiazida [inn-spanish]
isonicotinic acid (o-(carboxymethoxy)benzylidene)hydrazide
o-(isonicotinoylhydrazonomethinyl)phenoxyessigsaeure
aconiazide [inn]
2-[2-[(z)-(pyridine-4-carbonylhydrazinylidene)methyl]phenoxy]acetic acid
unii-8okq9ns8mo
13410-86-1
aconiazidum
aconiazida
8okq9ns8mo ,
4-22-00-00585 (beilstein handbook reference)
Q15633956

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Identifying the maximum safe dose (MAXSD) is an objective of both randomized clinical dose-finding studies for the safety endpoint and toxicological studies."( Identifying the maximum safe dose: a multiple testing approach.
Hauschke, D; Hothorn, LA, 2000)		0.31

Bioavailability

aconiazide's relative bioavailability (based on the area under the serum concentration-time curve) was 50. Compared with isoniazid tablets, aconiaZide's Relative Bioavailability (Based on the Area Under The Serum Concentration-time Curve) was 40.

ExcerptReferenceRelevance
"To determine the bioavailability and renal elimination of isoniazid, acetylisoniazid, monoacetylhydrazine, diacetylhydrazine, aconiazide, and 2-formylphenoxyacetic acid."( Pharmacokinetic evaluation of aconiazide, a potentially less toxic isoniazid prodrug.
Craig, LD; Iklé, D; Iseman, MD; James, GT; Kim, M; McCarthy, EA; Peloquin, CA, )		0.63
" Compared with isoniazid tablets, aconiazide's relative bioavailability (based on the area under the serum concentration-time curve) was 50."( Pharmacokinetic evaluation of aconiazide, a potentially less toxic isoniazid prodrug.
Craig, LD; Iklé, D; Iseman, MD; James, GT; Kim, M; McCarthy, EA; Peloquin, CA, )		0.7

Dosage Studied

ExcerptRelevanceReference
" The methods are illustrated with data from a dose-response study, and their performance is evaluated with a Monte Carlo simulation study."( Upper confidence limits on excess risk for quantitative responses.
Kodell, RL; West, RW, 1993)		0.29
"Reversed-phase HPLC methods are described for determining the stability and concentration certification of the antituberculosis prodrug aconiazide (ACON) in aqueous dosing solution and for assessing the concentrations of ACON and isoniazid (INH) in plasma from ACON-treated male and female Fischer-344 rats."( High-performance liquid chromatographic analysis of the antituberculosis drugs aconiazide and isoniazid.
Dooley, KL; Hansen, EB; Thompson, HC, 1995)		0.72
" Although risk-assessment procedures that attempt to utilize the quantitative information in such data have been proposed, there is no general agreement that these procedures are appreciably more efficient than common quantal dose-response procedures that operate on dichotomized continuous data."( A comparison of methods of benchmark-dose estimation for continuous response data.
Kodell, RL; West, RW, 1999)		0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (16.67)18.7374
1990's4 (66.67)18.2507
2000's1 (16.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.98 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.99 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (14.29%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
isoniazid
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).		3.2360carbohydrazideantitubercular agent;
drug allergen
hydrazine
diamine : Any polyamine that contains two amino groups.		1.9510azane;
hydrazines		EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
tiludronic acid
tiludronic acid: a bone resorption inhibitor; an antihypercalcemic agent; used in the tratment of Paget's disease; used in the treatment and prevention of osteoporosis; structure given in first source		210organochlorine compound
ConditionIndicatedRelationship StrengthStudiesTrials
Weight Reduction
[description not available]		01.9810
Weight Loss
Decrease in existing BODY WEIGHT.		01.9810
Weight Gain
Increase in BODY WEIGHT over existing weight.		02.420
Extra-Mammary Paget Disease
[description not available]		0210
Paget Disease, Extramammary
A rare cutaneous neoplasm that occurs in the elderly. It develops more frequently in women and predominantly involves apocrine gland-bearing areas, especially the vulva, scrotum, and perianal areas. The lesions develop as erythematous scaly patches that progress to crusted, pruritic, erythematous plaques. The clinical differential diagnosis includes squamous cell carcinoma in situ and superficial fungal infection. It is generally thought to be an adenocarcinoma of the epidermis, from which it extends into the contiguous epithelium of hair follicles and eccrine sweat ducts. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1478)		0210
Adverse Drug Event
[description not available]		0210
Drug-Related Side Effects and Adverse Reactions
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.		0210